Hostname: page-component-745bb68f8f-d8cs5 Total loading time: 0 Render date: 2025-02-06T09:19:15.869Z Has data issue: false hasContentIssue false

Re-treatment for intravenous immunoglobulin-resistant Kawasaki disease

Published online by Cambridge University Press:  23 April 2015

Xiaomin Guo
Affiliation:
Department of Pediatrics, Peking University First Hospital, Beijing, China
Yaqian Huang
Affiliation:
Department of Pediatrics, Peking University First Hospital, Beijing, China
Hongfang Jin
Affiliation:
Department of Pediatrics, Peking University First Hospital, Beijing, China
Junbao Du*
Affiliation:
Department of Pediatrics, Peking University First Hospital, Beijing, China
*
Correspondence to: Professor J. Du, Department of Pediatrics, Peking University First Hospital, Beijing 100034, China. Tel: +86 10 8357 3165; Fax: +86 10 6653 0532; E-mail: junbaodu1@126.com
Rights & Permissions [Opens in a new window]

Abstract

Type
Letters to the Editor
Copyright
© Cambridge University Press 2015 

Dear Sir,

We have read and appreciate your commentsReference Chandelia 1 regarding the article entitled “A meta-analysis of re-treatment for intravenous immunoglobulin-resistant Kawasaki disease”. Regarding the issue that the potential risk of publication bias might possibly occur, especially towards positive outcomes, a funnel plot would help out with the analysis of the bias. The relatively small sample number of the selected publications would likely result in publication bias as discussed in the manuscript.Reference Yang, Liu and Huang 2 Indeed, although over the past 10 years the incidence of Kawasaki disease as well as coronary artery lesions have significantly increased, there were a limited number of randomised-controlled trial studies investigating the re-treatment for children with intravenous immunoglobulin-resistant Kawasaki disease. Whether glucocorticoids should be used routinely for patients with intravenous immunoglobulin-resistant Kawasaki disease is still in need of studies with a large sample size.

We used fixed effects model in this meta-analysis, where the possible moderators such as the study design characteristics of the original articles might affect the results. Statistical tests showed that there was heterogeneity among the four selected articles; however, the heterogeneity made out by the statistical test could not explain the nature of heterogeneity, whether it was clinical heterogeneity or statistical heterogeneity. Random effects model would make the analysed results applicable to a larger set of studies. More rigorous original studies with a large sample size would definitely help us with the analysis.

References

1. Chandelia, S. A meta-analysis of re-treatment for intravenous immunoglobulin-resistant Kawasaki disease (Letter to the editor). Cardiol Young 2015.CrossRefGoogle Scholar
2. Yang, X, Liu, G, Huang, Y, et al. A meta-analysis of re-treatment for intravenous immunoglobulin-resistant Kawasaki disease. Cardiol Young 2015.CrossRefGoogle ScholarPubMed